8-姜酚抑制乳腺癌细胞增殖的分子机制研究

杨崇; 傅若秋; 高宁

doi:10.16016/j.1000-5404.201809200

您当前的位置：

首页 >

文章列表页 >

8-姜酚抑制乳腺癌细胞增殖的分子机制研究

基础医学 | 更新时间：2026-01-09

- 8-姜酚抑制乳腺癌细胞增殖的分子机制研究
- Molecular mechanism of inhibition of 8-gingerol on proliferation of breast cancer cells
- 第三军医大学学报 2019年41卷第5期页码：406-414
- 作者机构：
  
  400038 重庆，陆军军医大学(第三军医大学)药学与检验医学系生药学教研室
- 作者简介：
  
  [高宁, E-mail:gaoning59@163.comGAO Ning, E-mail:gaoning59@163.com
- 基金信息：
  
  国家自然科学基金面上项目(31571425)
- DOI：10.16016/j.1000-5404.201809200
  中图分类号： R285.5;R73-36;R737.9
- 收稿：2018-09-28，
  
  修回：2018-12-11，
  
  纸质出版：2019-03-15
- 稿件说明：
移动端阅览
杨崇, 傅若秋, 高宁. 8-姜酚抑制乳腺癌细胞增殖的分子机制研究[J]. 第三军医大学学报, 2019,41(5):406-414.

Chong YANG, Ruoqiu FU, Ning GAO. Molecular mechanism of inhibition of 8-gingerol on proliferation of breast cancer cells[J]. Journal of Third Military Medical University, 2019, 41(5): 406-414.
杨崇, 傅若秋, 高宁. 8-姜酚抑制乳腺癌细胞增殖的分子机制研究[J]. 第三军医大学学报, 2019,41(5):406-414. DOI： 10.16016/j.1000-5404.201809200.

Chong YANG, Ruoqiu FU, Ning GAO. Molecular mechanism of inhibition of 8-gingerol on proliferation of breast cancer cells[J]. Journal of Third Military Medical University, 2019, 41(5): 406-414. DOI： 10.16016/j.1000-5404.201809200.

摘要

目的

探讨8-姜酚抑制乳腺癌细胞增殖的分子机制。

方法

MTT法测定乳腺癌细胞MDA-MB-231细胞活性；流式细胞仪检测产生活性氧(reactive oxygen species

ROS)的细胞比例、细胞周期以及细胞凋亡；Western blot检测周期相关蛋白Cyclin D1和p-DCD2的表达。

结果

8-姜酚能明显抑制乳腺癌MDA-MB-231和MCF-7细胞的增殖活性，差异有统计学意义(

0.01)，72 h的IC

值分别为(22.06±2.93)、(35.77±5.96)μmol/L；流式细胞仪检测结果发现8-姜酚可导致乳腺癌细胞G

期阻滞，诱导细胞产生ROS；8-姜酚作用于MDA-MB-231和MCF-7细胞24 h后G

期细胞的百分比分别为(69.23±3.77)%、(65.87±3.76)%，与对照组G

期的细胞比例(47.39±1.97)%、(49.17±3.52)%相比，差异具有统计学意义(

0.01)；用NAC抑制ROS后减弱了8-姜酚对乳腺癌细胞G

期的阻滞作用，用P38抑制剂抑制P38蛋白磷酸化水平后也减弱了8-姜酚对乳腺癌细胞G

期的阻滞作用。Western blot结果显示8-姜酚可以上调MAPK信号通路中P38蛋白的磷酸化水平；并可下调G

期相关蛋白Cyclin D1和p-CDC2的表达，用NAC抑制ROS后减弱了8-姜酚对P38磷酸化水平上调作用的同时还减弱了8-姜酚对周期相关蛋白CyclinD1、p-CDC2的下调作用；用P38抑制剂抑制P38蛋白磷酸化水平后同样减弱了8-姜酚对周期相关蛋白CyclinD1、p-CDC2的下调作用。

结论

8-姜酚具有明显的抑制肿瘤增殖活性的作用，其作用机制可能为8-姜酚通过诱导乳腺癌细胞产生ROS从而导致MAPK信号通路中P38的磷酸化激活，进而引起乳腺癌细胞的周期阻滞。

Abstract

Objective

To investigate the effect of cell cycle on breast cancer cells by 8-gingerol.

Methods

The cell viability of breast cancer cells MDA-MB-231 and MCF-7 after treated by 8-gingerol at the doses of 0

30 or 40 μmol/L for 24

48 or 72 h was assessed by MTT assay. The cell cycle

apoptosis and proportion of cells producing ROS were measured by flow cytometry. The expression of cell cycle associated proteins

Cyclin D1 and p-CDC2 were detected by Western blot analysis.

Results

8-gingerol evidently inhibited the proliferation of breast cancer MDA-MB-231 and MCF-7 cells (

0.01). The inhibitory concentration of IC

were 22.06±2.93 and 35.77±5.96 μmol/

respectively in the breast cancer MDA-MB-231 and MCF-7 cells after 72 h treatment with 8-gingerol. The results of flow cytometry showed that 8-gingerol can cause G

phase arrest and induce cells to produce ROS in the breast cancer MDA-MB-231 and MCF-7 cells after treatment with 8-gingerol for 72 h. Flow cytometry found that 8-gingerol resulted in cell cycle arrest at G

phase cells was (69.23±3.77)% and (65.87±3.76)%

respectively in the MDA-MB-231 and MCF-7 cells after 8-gingerol treatment for 24 h

significantly higher than in the cells without treatment [(47.39±1.97)%

(49.17±3.52)%

0.01

]

. Pretreatment with NAC weakened the effect of 8-gingerol on G

phase arrest. Western blot results showed that 8-gingerol resulted in the decreases of Cyclin D1 and p-CDC2 levels

and upregulated the phosphorylation level of P38. The inhibition of ROS by NAC attenuated the up-regulation of phosphorylation of P38 by 8-gingerol and the down-regulation of cyclin-related proteins Cyclin D1 and p-CDC2. The inhibition of P38 phosphorylation by P38 inhibitors also attenuated the down-regulation of cyclin-associated proteins Cyclin D1 and p-CDC2 by 8-gingerol.

Conclusion

8-gingerol exhibits obviously inhibitory effects on breast cancer cell proliferation. The mechanism may be that 8-gingerol induces ROS in breast cancer cells

which leads to phosphorylation of P38 in the MAPK signaling pathway

and then leads to cell cycle arrest.

关键词

Keywords

references

BARRAGAN S, RUEDA C, FERNANDEZ M. Circular order aggregation and its application to cell-cycle genes expressions[J]. IEEE/ACM Trans Comput Biol Bioinform, 2017, 14(4):819-829.DOI:10.1109/TCBB.2016.2565469.

FUZER A M, LEE S Y, MOTT J D, et al . [10 ] -gingerol reverts malignant phenotype of breast cancer cells in 3D culture[J ] . J Cell Biochem, 2017, 118(9):2693-2699.DOI:10.1002/jcb.25906.

GENG S, ZHENG Y, MENG M, et al . Gingerol reverses the cancer-promoting effect of capsaic in by increased TRPV1 level in a urethane-induced lung carcinogenic model[J ] . J Agric Food Chem, 2016, 64(31):6203-6211.DOI:10.1021/acs.jafc.6b02480.

LI B, ZHANG L, ZHANG Z Y, et al . Differentiation of noncalculous periampullary obstruction: comparison of CT with negative-contrast CT cholangiopancreatography versus MRI with MR cholangiopancreatography[J ] . Eur Radiol, 2015, 25(2):391-401.DOI:10.1007/s00330-014-3430-4.

TERVONEN H, FOLIAKI S, BRAY F, et al . Cancer epidemiology in the small nations of Pacific Islands[J ] . Cancer Epidemiol, 2017, 50(Pt B):184-192.DOI:10.1016/j.canep.2017.09.002.

JANSSON S, BENDAHL P O, GRABAU D A, et al . The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer[J ] . PLoS ONE, 2014, 9(7): e102176.DOI:10.1371/journal.pone.0102176.

LIM S, KALDIS P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation[J]. Development, 2013, 140(15):3079- 3093.DOI:10.1242/dev.091744.

ANGTHONG W, JIARAKOOP K, TANGTIANG K. Differentiation of benign and malignant ampullary obstruction by multi-row detector CT[J]. Jpn J Radiol, 2018,36(8):477-488.DOI:10.1007/s11604-018-0746-z.

LI J M, BROOKS G. Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system; potential targets for therapy?[J]. Eur Heart J, 1999, 20(6):406-420.

GARRIDO-CASTRO A C, GOEL S. CDK4/6 inhibition in breast cancer: mechanisms of response and treatment failure[J]. Curr Breast Cancer Rep, 2017, 9(1):26-33.DOI:10.1007/s12609-017-0232-0.

ZHU S, BJORGE J D, CHENG H C, et al . Decreased CHK protein levels are associated with Src activation in colon cancer cells[J ] . Oncogene, 2008, 27(14):2027-2034.DOI:10.1038/sj.onc.1210838.

MIN Y H, KIM W, KIM J E. The Aurora kinase A inhibitor TC-A2317 disrupts mitotic progression and inhibits cancer cell proliferation[J]. Oncotarget, 2016, 7(51):84718-84735.DOI:10.18632/oncotarget.12448.

TANAKA N, PATEL A A, WANG J, et al . Wee-1 kinase inhibition sensitizes high-risk HPV+HNSCC to apoptosis accompanied by downregulation of MCl-1 and XIAP antiapoptotic proteins[J ] . Clin Cancer Res, 2015, 21(21):4831-4844.DOI:10.1158/1078-0432.CCR-15-0279.

BRILL E, YOKOYAMA T, NAIR J, et al . Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer[J ] . Oncotarget, 2017, 8(67):111026-111040.DOI:10.18632/oncotarget.22195.

MAETENS M, BROWN D, IRRTHUM A, et al . The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group[J ] . NPJ Breast Cancer, 2017, 3:23.DOI:10.1038/s41523-017-0026-6.

VAN DEN BOSSCHE J, LARDON F, DESCHOOLMEESTER V, et al . Spotlight on volasertib: preclinical and clinical evaluation of a promising Plk1 inhibitor[J ] . Med Res Rev, 2016, 36(4):749-786.DOI:10.1002/med.21392.

LEIJEN S, VAN GEEL R M, SONKE G S, et al . Phase Ⅱ study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months[J ] . J Clin Oncol, 2016, 34(36):4354-4361.DOI:10.1200/JCO.2016.67.5942.

丁贤彬, 吕晓燕, 毛德强, 等. 2006-2014年重庆市肿瘤登记地区卵巢癌发病率及趋势变化[J].中华预防医学杂志. 2016, 50(3):274-276.DOI:10.3760/cma.j.issn.0253-9624.2016.03.017.

DING X B, LYU X Y, MAO D Q, et al . Incidence and trend change of oophoroma in 11 tumor registration stations, Chongqing[J ] . Chin J Prevent Med, 2016, 50(3):274-276.DOI:10.3760/cma.j.issn.0253-9624.2016.03.017.

ZHU Y, WANG F, ZHAO Y, et al . Gastroprotective [6 ] -gingerol aspirinate as a novel chemopreventive prodrug of aspirin for colon cancer[J ] . Sci Rep, 2017, 7(1):40119.DOI:10.1038/srep40119.

PYENSON B S, TOMICKI S M. Lung cancer screening: a cost-effective public health imperative[J].Am J Public Health, 2018, 108(10):1292-1293.DOI:10.2105/AJPH.2018.304659.

PRENDEVILLE S, Al-BOZOM I, COMPÉRAT E, et al . Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin? [J ] . Histopathology, 2017, 71(6):926-933.DOI:10.1111/his.13330.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

基于中国人群的雌激素受体表达新分层（低/中/高）可更精准地预测HR⁺/HER2^-早期乳腺癌患者的预后

RANKL通过ROS介导HIF-1α下调促进自噬和破骨细胞分化

活性氧清除性Ce6-鲁米诺脂质体的制备及其对小鼠放射性肺炎的保护作用研究

新型中性粒细胞响应性发光纳米胶束的构建及其在小鼠烧伤模型成像中的应用

二氢杨梅素通过抑制mTOR信号通路抑制乳腺癌细胞迁移和侵袭